Healthcare, Pharma & Life Sciences

Minaris, Asimov Partner to Boost AAV Gene Therapy Production Titers

Image
Minaris, Asimov Partner to Boost AAV Gene Therapy Production Titers

Philadelphia and Boston – September 25, 2026 -- Minaris, a global cell and gene therapy CDMO, has partnered with synthetic biology firm Asimov to integrate proprietary OXGENE viral vector technology into Asimov's AAV Edge producer cell lines, targeting higher manufacturing titers and improved product quality for adeno-associated virus (AAV) gene therapies.

Stable production systems aim to replace costly transient manufacturing

Most AAV programs currently rely on transient production, requiring multiple GMP plasmids to be transfected for every batch. This method drives up costs, limits scalability, and can produce inconsistent product quality. Stable production systems have historically been difficult to develop due to the complexity and interdependency of viral genetics involved.

MDpanel Names Nariwal COO, Andrews Chief Client Officer

Image
MDpanel Names Nariwal COO, Andrews Chief Client Officer

Los Angeles – September 25, 2026 -- MDpanel, one of the largest providers of expert medical opinions in the United States, has appointed Manish Nariwal as Chief Operating Officer and Jim Andrews as Chief Client Officer, both reporting to Chairman and CEO Jason Erdell.

Pomdoctor Bets on Hardware-AI-Payment Model for Digital Health

Guangzhou – September 25, 2026 -- Pomdoctor Limited (NASDAQ: POM) outlined a differentiated "hardware plus AI plus payment" infrastructure model that it says sets the company apart from traditional internet healthcare platforms, which typically operate in silos around discrete services such as online consultations or pharmaceutical transactions.

Pomdoctor targets full-cycle predictive healthcare integration

The Guangzhou-based digital healthcare company said its system is designed to combine continuous health monitoring, AI-powered analysis, physician intervention, healthcare payment and fulfillment into a single closed-loop ecosystem, rather than offering standalone services.

Basecamp Research Raises $140M to Advance AI-Designed Cell Therapies

Image
Basecamp Research Raises $140M to Advance AI-Designed Cell Therapies

London and Boston – September 25, 2026 -- Basecamp Research has closed a $140 million oversubscribed Series C financing to train new EDEN foundation models and push a pipeline of AI-designed therapeutics toward clinical development.

S32 leads a syndicate spanning NVIDIA, Anthropic-adjacent backers and sovereign funds

The round was led by S32, with participation from NVIDIA, Menlo Ventures' Anthology Fund, Catalio Capital Management, European Tech Collective, Firebrand River Capital, Inception Fund, King Philanthropies, NATO Innovation Fund, PostScriptum, Redalpine, The Rockefeller Foundation, Singular, Sovereign AI and True Ventures. Andy Conrad, General Partner at S32 and former CEO of Google's Verily, joins Basecamp's Board of Directors.

Clywedog's Balomenib Cuts HbA1c 0.77% Three Months Post-Dosing

Image
Clywedog's Balomenib Cuts HbA1c 0.77% Three Months Post-Dosing

Dover, Del. – September 25, 2026 -- Clywedog Therapeutics, Inc. reported that its investigational menin inhibitor balomenib produced a placebo-adjusted mean HbA1c reduction of 0.77% at Week 12 (p0.01) and 0.70% at Week 16 (p0.05) in a Phase 1b trial, effects recorded three months after the drug's final dose following just three weeks of treatment.

ISPE Sets October Washington Summit With Lonza, Lilly CEOs Headlining

Image
ISPE Sets October Washington Summit With Lonza, Lilly CEOs Headlining

North Bethesda, Md. – September 24, 2026 -- The International Society for Pharmaceutical Engineering (ISPE) will convene its 2026 Annual Meeting & Expo in Washington, D.C. from October 18-21, drawing pharmaceutical manufacturing leaders for four days of hybrid sessions combining in-person and virtual attendance.

Lonza and Eli Lilly executives headline keynote lineup on manufacturing innovation

Wolfgang Wienand, PhD, CEO of Lonza, will present "The Lonza Engine: Manufacturing the Medicines of Tomorrow," while Kevin Trivett, Senior Vice President of Device and Packaging Operations Manufacturing at Eli Lilly and Company, delivers "Lilly: Embracing Technology to Reach Patients." Additional featured speakers include Marla Phillips, PhD, CEO and President of Pathway for Patient Health LLC, addressing AI and human oversight in manufacturing loops, and cancer survivor and research advocate Jamie Valvano.

Sobi's Gamifant Data Get Best Poster Nod at HS2026 in Rotterdam

Stockholm – September 24, 2026 -- Sobi (STO: SOBI) will present new clinical data on its rare-disease drug Gamifant (emapalumab) at the 2026 Annual Meeting of the Histiocyte Society (HS2026), running September 26-29 in Rotterdam, the Netherlands, with a pooled survival analysis nominated for the meeting's top poster prize.

Pooled transplant-survival analysis earns Robert J. Arceci Prize nomination

The accepted abstract set includes a new pooled analysis of pre- and post-transplant survival outcomes in primary haemophagocytic lymphohistiocytosis (HLH), drawing on data across three prospective trials. Sobi said the analysis was selected as one of the ten highest-scoring poster abstracts at HS2026 and has been nominated for the Robert J. Arceci Prize for Best Poster.

Sectra One Cloud Goes Live at Northeast Georgia Medical Center

Linköping – September 24, 2026 -- Northeast Georgia Medical Center has gone live with Sectra's cloud-based enterprise imaging platform, Sectra One Cloud, under a five-year contract covering an expected annual imaging volume of around 850,000 exams.

Hospital deploys radiology, breast imaging and cardiology modules in first rollout phase

The Gainesville-based flagship hospital of Northeast Georgia Health System initially activated three specialty modules on the unified platform, allowing clinicians across sites to view, share and report on patient studies from a single system rather than separate applications tied to each specialty.

Richard Wright, Executive Director of Imaging Services for Northeast Georgia Medical Center, said the consolidated workflow has reduced steps between viewing studies and finalizing reports, and enables clinicians at different sites to consult on the same case.

Daewoong Completes 104-Patient Phase 2 Enrollment for IPF Drug Bersiporocin

Image
Daewoong Completes 104-Patient Phase 2 Enrollment for IPF Drug Bersiporocin

Barcelona – September 24, 2026 -- Daewoong Pharmaceutical has completed enrollment of 104 idiopathic pulmonary fibrosis (IPF) patients in its global Phase 2 trial of Bersiporocin (DWN12088), with top-line results now expected in the first half of 2027.

Trial spans South Korea and the US with balanced enrollment

Of the 104 patients, 55 (52.9%) were enrolled in South Korea and 49 (47.1%) in the United States. The company presented full baseline patient characteristics at the European Respiratory Society (ERS) Congress 2026 in Barcelona on September 6, following interim data shared earlier at KATRDIC 2025.

ULC Brings Gary Brecka Longevity Tour to Boulder, Denver Oct. 4

Image
ULC Brings Gary Brecka Longevity Tour to Boulder, Denver Oct. 4

Boulder, Colo. – September 24, 2026 -- Ultimate Longevity Center (ULC), a Sequel Brands franchise with more than 300 territories sold globally, will host two free live events with human performance expert Gary Brecka in Colorado on Sunday, October 4.

ULC schedules back-to-back Colorado events after strong Los Angeles turnout

Brecka will appear at Macky Auditorium in Boulder at 10:30 AM MT and at the Fillmore Auditorium in Denver at 3:30 PM MT, both hosted by ULC in collaboration with Ultimate Human. The dates follow his August appearance at Peacock Theater in Los Angeles, which drew thousands of attendees.